Cleveland, OH, United States of America

Annette Burkhouse

This inventor holds 2 USPTO granted patents. Top assignee: Case Western Reserve University. Active years: 2018-2021.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2018-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Annette Burkhouse: Innovator in HIV Vaccine Development

Introduction

Annette Burkhouse is a prominent inventor based in Cleveland, OH (US). She has made significant contributions to the field of immunology, particularly in the development of vaccines against HIV. With a total of 2 patents, her work is paving the way for advancements in medical science.

Latest Patents

Burkhouse's latest patents focus on a method for inducing an immune response against HIV. This innovative approach involves preparing an HIV-1 gp120 envelope protein coding sequence particle with an N425K mutation. The process includes introducing this coding sequence into an expression construct using yeast homologous recombination. Following this, a cell is transfected with the expression construct, allowing the HIV-1 particle to be secreted by the cell. The secreted HIV-1 particle, along with a pharmaceutically acceptable carrier, is then administered to the subject, stimulating an immune response.

Career Highlights

Annette Burkhouse is affiliated with Case Western Reserve University, where she continues her research and development efforts. Her work is characterized by a commitment to advancing healthcare solutions through innovative scientific research.

Collaborations

One of her notable collaborators is Eric J Arts, with whom she has worked closely on various projects related to HIV research.

Conclusion

Annette Burkhouse's contributions to the field of HIV vaccine development highlight her role as a leading inventor in medical science. Her innovative methods and dedication to research are making a significant impact on public health.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…